HUMAN FIBRINOGEN Chemical Properties

storage temp. 

-20°C

solubility 

0.9% NaCl: soluble

form 

powder

color 

white

biological source

r at plasma

Water Solubility 

water: 25mg/mL

InChI

InChI=1/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5+,6+/s3

InChIKey

FBPFZTCFMRRESA-ZCLOERBHNA-N

SMILES

C(O)[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO |&1:2,4,6,8,r|

EPA Substance Registry System

Fibrinogens (9001-32-5)

Safety Information

Hazard Codes 

B

WGK Germany 

3

F 

10-21

TSCA 

TSCA listed

Storage Class

13 - Non Combustible Solids

MSDS

• Language:English Provider:SigmaAldrich

HUMAN FIBRINOGEN Usage And Synthesis

Chemical Properties

White or grayish amorphous substance.

Uses

A soluble plasma glycoprotein, produced by the liver, that is converted by thrombin into fibrin during the blood coagulation process. Fibrinogen is a natural blood protein involved in the coagulation process. It is used instead of traditional sources of fibrinogen such as the blood products, fresh frozen plasma and cryoprecipitate. It helps in blood clot formation.

Uses

Diagnostic aid (vascular patency); radioactive agent.

Uses

Fibrinogen from rat plasma has been used:

• in the preparation of growth factor solutions
• to apply on discontinuous SDS-polyacrylamide gels for the detection of IgG (immunoglobulins) type antibodies by immunoblot analysis
• to mix with cell suspension to form a clot and retain the cells for avoiding its dispersion during transplantation

Definition

A sterile fraction of normal human blood plasma, dried from the frozen state. In solution, it has the property of being converted into insoluble fibrin when thrombin is added. It is an essential factor in the blood-clotting mechanism.

General Description

Fibrinogen, or Factor I, is a blood protein that is involved in clotting and is converted to fibrin by thrombin. Fibrinogen has an approximate molecular weight of 340 kDa

Biochem/physiol Actions

Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source.

Synthesis

China has abundant pig blood resources, but due to the production process conditions are not mature enough, resulting in the utilization of pig blood resources is less than 1%. 2006 for the first time to use freeze-thawing method to extract pig blood fibrinogen, 1L of plasma can be extracted fibrinogen 2.67g, the sample of fibrinogen content of 82.6%, the extraction rate of 91.0%. The fibrinogen content of the prepared fibrinogen sample was 84.3%, and the extraction rate of fibrinogen was 88%; the content of fibrinogen isolated by freeze-thaw extraction was 2.81g/L, and its extraction rate was 89.05%; the fibrinogen was isolated by cold ethanol intoxication precipitation and ion-exchange chromatography, and the fibrinogen content of the fibrinogen samples was 71.1% and 68.0%, respectively and the extraction rates were 88.1% and 95.0%, respectively; Fibrinogen was extracted by the modified cold precipitation method, and compared with the traditional precipitation method; the fibrinogen content obtained by the modified cold precipitation method was (196.4??23.3) mg/200mLFFP (fresh frozen plasma), while the fibrinogen content obtained by the traditional precipitation method was (184.6??21.7) mg/200mLFFP, which indicated that the fibrinogen content in the fibrinogen samples was (184.6??21.7) mg/200mLFFP. 200 mLFFP, which indicated that the extraction rate of the modified cold precipitation method was higher than that of the traditional precipitation method; the average concentration of fibrinogen obtained from the extraction of fibrinogen by repeated cold precipitation was (54.2??19.9) g/L; the effects of the four precipitation methods (freezing, ethanol, polyethylene glycol, and ammonium sulfate precipitation) on the isolation of fibrinogen from porcine plasma were investigated, and it was concluded that ammonium sulfate precipitation method The separation effect of the ammonium sulfate precipitation method was found to be optimal.

Purification Methods

A likely impurity is plasminogen. It is purified by glycine precipitation [Mosesson & Sherry Biochemistry 5 2829 1966] to obtain fractions 1-2, then further purified [Blomb.ck & Blomb.ck Arkiv Kemi 10 415 1956] and contaminating plasminogen is removed by passage through a lysine-Sepharose column. Such preparations are at least 95% clottable as determined by Mosesson and Sherry's method (above ref.) in which the OD280 is measured before and after clotting with 5 Units/mL of thrombin (> 3000U/mg). All fibrinogen preparations are treated with calf intestinal alkaline phosphatase to convert any fibrinogen peptide-AP to fibrinogen peptide-A by removing serine-bound phosphate. Solutions are then lyophilised and stored at -20o. [Higgins & Shafer J Biol Chem 256 12013 1981.] It is sparingly soluble in H2O. Aqueous solutions are viscous with isoelectric point at pH 5.5. It is readily denatured by heating above 56o or by chemical agents, e.g. salicylaldehyde, naphthoquinone sulfonates, ninhydrin or alloxan. [Edsall et al. J Am Chem Soc 69 2731 1947, Purification: Cama et al. Naturwissenschaften 48 574 1961, Lorand & Middlebrook Science 118 515 1953, cf. Fuller in Methods Enzymol 163 474 1988.] For plasminogen-deficient fibrinogen from blood plasma, the anticoagulated blood is centrifuged and the plasma is frozen and washed with saline solution. It is treated with charcoal, freeze-thawed and dialysed versus Tris/NaCl buffer. [Maxwell & Nikel Biochemical Preparations 12 16 1968.]

HUMAN FIBRINOGEN(9001-32-5)Related Product Information

• Cupric acetylacetonate
• Ferric acetylacetonate
• N-BUTYLISOCYANIDE
• Tosylmethyl isocyanide
• TRIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)DYSPROSIUM(III)
• TERT-BUTYL ISOCYANIDE
• METHYL ISOCYANOACETATE
• DICHLORO(ETHYLENEDIAMINE)PLATINUM(II)
• TRIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)EUROPIUM(III)
• SALCOMINE
• 1,1,3,3-TETRAMETHYLBUTYL ISOCYANIDE
• 2,4-PENTANEDIONE, SILVER DERIVATIVE
• Tris(2,4-pentanedionato)chroMiuM(III)
• Ethyl isocyanoacetate
• Benzyl isocyanide
• COBALT(II) ACETYLACETONATE
• Aluminum acetylacetonate
• PHENYLSELENOL